Disclosed are compounds of the formula ##STR00001## or a pharmaceutically acceptable salt thereof, wherein: M.sup.1 and M.sup.3 are CH or N; M.sup.2 is CH, CF or N; Y is --C(.dbd.O)--, --C(.dbd.S)--, --(CH.sub.2).sub.q--, --C(.dbd.NOR.sup.7)-- or --SO.sub.1-2--; Z is a bond or optionally substituted alkylene or alkenylene; R.sup.1 is H, alkyl, alkenyl, or optionally substituted cycloalkyl, aryl, heteroaryl, heterocycloalkyl or a group of the formula: ##STR00002## where ring A is a monoheteroaryl ring; R.sup.2 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma or cognition deficit disorders using said compounds, alone or in combination with other agents.

Web www.patentalert.com

< Band stop filter employing a capacitor and an inductor tank circuit to enhance MRI compatibility of active implantable medical devices

> Reducing protein A leaching during protein A affinity chromatography

~ 00452